Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $405.27 which represents a slight increase of $8.00 or 2.01% from the prior close of $397.27. The stock opened at $391.87 ...